Tonghua Dongbao Pharmaceutical Co Ltd (600867) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tonghua Dongbao Pharmaceutical Co Ltd (600867) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥62.99 Million ≈ $9.22 Million USD) by net assets (CN¥7.14 Billion ≈ $1.04 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Tonghua Dongbao Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.
Tonghua Dongbao Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Tonghua Dongbao Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tonghua Dongbao Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tonghua Dongbao Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elkem ASA
OL:ELK
|
0.023x |
|
Hyosung Corp
KO:004800
|
0.117x |
|
Payoneer Global Inc
NASDAQ:PAYO
|
0.079x |
|
BaoJi Titanium Industry Co Ltd
SHG:600456
|
0.022x |
|
Maxvision Technology Corp
SHE:002990
|
0.031x |
|
GavYam Lands Corp Ltd
TA:GVYM
|
0.019x |
|
Shenzhen Mason Technologies Co Ltd
SHE:002654
|
0.155x |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
-0.126x |
Annual Cash Flow Conversion Efficiency for Tonghua Dongbao Pharmaceutical Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Tonghua Dongbao Pharmaceutical Co Ltd from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Tonghua Dongbao Pharmaceutical Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥7.11 Billion ≈ $1.04 Billion |
CN¥689.23 Million ≈ $100.86 Million |
0.097x | +35.00% |
| 2024-12-31 | CN¥6.40 Billion ≈ $936.58 Million |
CN¥459.74 Million ≈ $67.27 Million |
0.072x | -39.83% |
| 2023-12-31 | CN¥7.22 Billion ≈ $1.06 Billion |
CN¥861.52 Million ≈ $126.07 Million |
0.119x | -9.40% |
| 2022-12-31 | CN¥6.55 Billion ≈ $958.41 Million |
CN¥863.09 Million ≈ $126.30 Million |
0.132x | -27.75% |
| 2021-12-31 | CN¥6.22 Billion ≈ $910.21 Million |
CN¥1.13 Billion ≈ $166.02 Million |
0.182x | -14.95% |
| 2020-12-31 | CN¥5.56 Billion ≈ $813.52 Million |
CN¥1.19 Billion ≈ $174.47 Million |
0.214x | -6.77% |
| 2019-12-31 | CN¥5.01 Billion ≈ $732.95 Million |
CN¥1.15 Billion ≈ $168.60 Million |
0.230x | +24.18% |
| 2018-12-31 | CN¥4.73 Billion ≈ $692.77 Million |
CN¥876.94 Million ≈ $128.32 Million |
0.185x | -12.56% |
| 2017-12-31 | CN¥4.54 Billion ≈ $663.97 Million |
CN¥961.19 Million ≈ $140.65 Million |
0.212x | +15.15% |
| 2016-12-31 | CN¥3.95 Billion ≈ $577.31 Million |
CN¥725.76 Million ≈ $106.20 Million |
0.184x | +54.81% |
| 2015-12-31 | CN¥2.48 Billion ≈ $362.76 Million |
CN¥294.58 Million ≈ $43.11 Million |
0.119x | +24.69% |
| 2014-12-31 | CN¥2.16 Billion ≈ $316.15 Million |
CN¥205.89 Million ≈ $30.13 Million |
0.095x | -13.08% |
| 2013-12-31 | CN¥2.02 Billion ≈ $295.04 Million |
CN¥221.06 Million ≈ $32.35 Million |
0.110x | +12.35% |
| 2012-12-31 | CN¥1.99 Billion ≈ $291.37 Million |
CN¥194.32 Million ≈ $28.44 Million |
0.098x | +468.21% |
| 2011-12-31 | CN¥2.08 Billion ≈ $304.07 Million |
CN¥-55.07 Million ≈ $-8.06 Million |
-0.027x | -128.63% |
| 2010-12-31 | CN¥1.73 Billion ≈ $253.53 Million |
CN¥160.40 Million ≈ $23.47 Million |
0.093x | -9.39% |
| 2009-12-31 | CN¥1.63 Billion ≈ $238.04 Million |
CN¥166.20 Million ≈ $24.32 Million |
0.102x | +58.67% |
| 2008-12-31 | CN¥1.43 Billion ≈ $209.78 Million |
CN¥92.31 Million ≈ $13.51 Million |
0.064x | -18.33% |
| 2007-12-31 | CN¥1.53 Billion ≈ $224.47 Million |
CN¥120.94 Million ≈ $17.70 Million |
0.079x | -36.33% |
| 2006-12-31 | CN¥1.28 Billion ≈ $186.72 Million |
CN¥158.00 Million ≈ $23.12 Million |
0.124x | +80.01% |
| 2005-12-31 | CN¥1.34 Billion ≈ $196.19 Million |
CN¥92.23 Million ≈ $13.50 Million |
0.069x | +592.91% |
| 2004-12-31 | CN¥1.33 Billion ≈ $194.05 Million |
CN¥13.17 Million ≈ $1.93 Million |
0.010x | -69.43% |
| 2003-12-31 | CN¥1.40 Billion ≈ $205.04 Million |
CN¥45.51 Million ≈ $6.66 Million |
0.032x | +38.36% |
| 2002-12-31 | CN¥1.36 Billion ≈ $199.45 Million |
CN¥31.99 Million ≈ $4.68 Million |
0.023x | -72.51% |
| 2001-12-31 | CN¥1.38 Billion ≈ $201.72 Million |
CN¥117.73 Million ≈ $17.23 Million |
0.085x | +317.87% |
| 2000-12-31 | CN¥1.43 Billion ≈ $208.52 Million |
CN¥29.12 Million ≈ $4.26 Million |
0.020x | +130.19% |
| 1999-12-31 | CN¥1.40 Billion ≈ $205.54 Million |
CN¥-95.09 Million ≈ $-13.91 Million |
-0.068x | +71.02% |
| 1998-12-31 | CN¥928.90 Million ≈ $135.93 Million |
CN¥-216.98 Million ≈ $-31.75 Million |
-0.234x | -- |
About Tonghua Dongbao Pharmaceutical Co Ltd
Tonghua Dongbao Pharmaceutical Co., Ltd. researches, develops, produces, and markets pharmaceuticals in China. It offers human insulin injections; insulin glargine injections; insulin aspart injections; liraglutide injections; and proprietary Chinese medicine. The company also provides insulin pen and pen needles; and chronic disease management platform, a diabetes management platform for drug tr… Read more